Learn more →
Back to Expert Scholars
Translational Medicine / 转化医学Cancer Nutrition & Cachexia

Charles Loprinzi

查尔斯·洛普林齐

MD

🏢Mayo Clinic(梅奥诊所)🌐USA

Regis Professor of Breast Cancer Research, Department of Oncology肿瘤科乳腺癌研究Regis讲席教授

70
h-index
3
Key Papers
3
Awards
3
Key Contributions

👥Biography 个人简介

Charles Loprinzi is a preeminent Mayo Clinic oncologist and clinical trialist who has shaped supportive oncology through landmark trials on cancer-related weight loss, appetite stimulation with megestrol acetate, and symptom management. His work on megestrol and weight gain established a foundational pharmacological approach to cancer cachexia.

Share:

🧪Research Fields 研究领域

Cancer Symptom Management癌症症状管理
Megestrol Acetate醋酸甲地孕酮
Hot Flashes潮热
Supportive Oncology支持性肿瘤学

🎓Key Contributions 主要贡献

Megestrol Acetate for Cancer Cachexia

Conducted pivotal randomized trials establishing megestrol acetate as an effective appetite stimulant and weight-gain agent in cancer cachexia, leading directly to FDA approval for this indication.

Dose Optimization of Appetite Stimulants

Performed dose-response trials of megestrol acetate defining optimal dosing for weight gain while minimizing toxicity, directly informing clinical prescribing guidelines.

Comprehensive Cancer Symptom Research

Led NCCTG cooperative group trials across a broad portfolio of cancer supportive care including fatigue, hot flashes, neuropathy, and anorexia, establishing an evidence base for symptom control.

Representative Works 代表性著作

[1]

Megestrol acetate for the prevention of hot flashes

New England Journal of Medicine (1994)

Randomized trial demonstrating megestrol acetate efficacy for cancer-related hot flashes, expanding the drug's supportive care applications beyond appetite stimulation.

[2]

Randomized comparison of megestrol acetate versus dexamethasone versus fluoxymesterone for the treatment of cancer anorexia/cachexia

Journal of Clinical Oncology (1999)

Three-arm trial establishing megestrol acetate superiority for weight gain and appetite in cancer cachexia, with direct impact on supportive care guidelines.

[3]

Venlafaxine in management of hot flashes in survivors of breast cancer: a randomised controlled trial

The Lancet (2000)

Landmark trial demonstrating venlafaxine efficacy for hot flashes in breast cancer survivors, opening non-hormonal management pathways.

🏆Awards & Recognition 奖项与荣誉

🏆ASCO Distinguished Achievement Award
🏆Multinational Association of Supportive Care in Cancer Lifetime Achievement Award
🏆Mayo Clinic Distinguished Clinician-Scientist Award

📄Data Sources 数据来源

Last updated: 2026-01-15 | All information from publicly available academic sources

关注 查尔斯·洛普林齐 的研究动态

Follow Charles Loprinzi's research updates

留下邮箱,当我们发布与 Charles Loprinzi(Mayo Clinic)相关的新研究或访谈时,我们会通知你。

我们不会泄露你的信息,也不会发送无关内容。随时可以退订。

Explore More Experts

Discover the researchers shaping the future of cancer treatment